Cargando…

Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma

Brain metastasis of osteosarcoma are rare but carry a dismal prognosis. Despite the advances in both systemic immunotherapy and localized radiation, it is still difficult to treat brain metastasis, with less than 12 months of survival from the time of diagnosis for most patients. Currently, there is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Liming, Wu, Hao, Qian, Wenkang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036860/ https://www.ncbi.nlm.nih.gov/pubmed/29992089 http://dx.doi.org/10.1016/j.jbo.2018.05.002

Ejemplares similares

Blockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma
por: Nastasi, Nicoletta, et al.
Publicado: (2023)

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
por: Lussier, Danielle M, et al.
Publicado: (2015)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
por: Liu, Xiaoqiang, et al.
Publicado: (2019)

Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade
por: Velu, Vijayakumar, et al.
Publicado: (2008)

PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma
por: Davern, Maria, et al.
Publicado: (2022)

Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade
por: Ferrere, Gladys, et al.
Publicado: (2021)

Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
por: Serganova, Inna, et al.
Publicado: (2016)

Enhancement of T cell immunity to osteosarcoma through modulation of PD-1/PD-L1 interactions
por: Lussier, Danielle M, et al.
Publicado: (2013)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Carbon ion irradiation enhances the antitumor efficacy of dual immune checkpoint blockade therapy both for local and distant sites in murine osteosarcoma
por: Takahashi, Yutaka, et al.
Publicado: (2019)

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
por: Maron, Steven B., et al.
Publicado: (2023)

Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
por: Gao, Yaohui, et al.
Publicado: (2021)

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
por: Page, David B., et al.
Publicado: (2019)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer
por: Wang, Yue, et al.
Publicado: (2018)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin
por: Chen, Shaomeng, et al.
Publicado: (2021)

ICSBP-induced PD-L1 enhances osteosarcoma cell growth
por: Sung, Jee Young, et al.
Publicado: (2022)

Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade
por: Läubli, Heinz, et al.
Publicado: (2017)

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
por: Liu, David, et al.
Publicado: (2019)

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
por: Graham, Laura S., et al.
Publicado: (2020)

Correction To: Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
por: Gao, Yaohui, et al.
Publicado: (2021)

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma
por: Parakh, Sagun, et al.
Publicado: (2021)

Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy
por: Zhou, Yuqing, et al.
Publicado: (2022)

Exceptional response to PD-1 inhibition immunotherapy in advanced metastatic osteosarcoma with tumor site infection
por: Li, Meng, et al.
Publicado: (2022)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma
por: Wang, Chao, et al.
Publicado: (2020)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
por: Zhao, Rui, et al.
Publicado: (2020)

PD-1 Blockade in Anaplastic Thyroid Carcinoma
por: Capdevila, Jaume, et al.
Publicado: (2020)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-L1 blockade enhances anti-tumor efficacy of NK cells
por: Oyer, Jeremiah L., et al.
Publicado: (2018)

PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
por: Azad, Abul, et al.
Publicado: (2016)

Enhancement of Vaccine-Induced T-Cell Responses by PD-L1 Blockade in Calves
por: Okagawa, Tomohiro, et al.
Publicado: (2023)

Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)

Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
por: Beckermann, Kathryn E., et al.
Publicado: (2017)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f0be4gqkdc1f5qqgep8cs7osjm